Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenkui Tongmai Granules is a Traditional Chinese Medicine (TCM) formulation developed by the Jiangsu Provincial Hospital of Traditional Chinese Medicine for the treatment of chronic heart failure (CHF). It is specifically indicated for patients presenting with the TCM syndrome of Qi deficiency and blood stasis. The preparation is typically used as an adjunctive therapy alongside guideline-directed medical treatments. Its therapeutic mechanism, based on TCM principles, involves tonifying Qi, warming Yang, and promoting blood circulation to resolve stasis, thereby improving cardiac function and alleviating symptoms such as dyspnea and fatigue. Clinical evaluation, including multi-center randomized controlled trials (e.g., ChiCTR2100044900), has focused on its efficacy in improving NYHA functional class, 6-minute walk distance, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenkui Tongmai Granules.